MYLS22 是首创的，选择性视神经萎缩 1 (OPA1) 抑制剂。MYLS22 可以靶向内皮细胞 OPA1 减少肿瘤的生长，通过影响 NFkB 活性和血管生成基因表达抑制血管生成。
货号:ajcx29532
CAS:306959-01-3
分子式:C24H21N5O2S
分子量：443.52
溶解度:DMSO: 83.33 mg/mL (187.88 mM)
纯度：98%
存储：Store at -20°C
库存：现货

Background:

MYLS22 is a first-in-class and selective optic atrophy 1 (OPA1) inhibitor. MYLS22 can target endothelial OPA1 to curtail tumor growth and inhibits angiogenesis by impinging on NFkB activity and on angiogenic gene expression[1].

MYLS22 (10 mg/kg/die; peritumoral injection; every 2 days for 14 days) causes the tumor growth curtailed mice[1]. Animal Model: 6-week-old C57BL6/J mice with B16F10 melanomas[1]

[1]. StÉphanie Herkenne, et al. Developmental and Tumor Angiogenesis Requires the Mitochondria-Shaping Protein Opa1. Cell Metab. 2020 May 5;31(5):987-1003.e8.